AstraZeneca/MedImmune Synergies An Advantage In Immune-Mediated Cancer Therapies
Executive Summary
AstraZeneca’s ability to combine its small molecules with MedImmune’s biologics gives the company an edge in the burgeoning field of immune-mediated cancer therapies, MedImmune’s oncology iMed chief said in Washington, D.C. April 7 at the AACR annual meeting.
You may also be interested in...
Cancer Checkpoint Roundup: Big Pharmas Advance Ahead of ASCO
During first-quarter earnings calls and ahead of the upcoming American Society of Clinical Oncology meeting, big pharma execs stressed the importance of developing immunotherapies in a range of cancers and highlighted the progress made so far.
Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key
AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.